NCT01341457
Completed
Phase 1
A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 17
- Locations
- 1
- Primary Endpoint
- Number of Participants With Dose Limiting Toxicity (DLT)
Overview
Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have histological or cytological or imaging evidence of a diagnosis of cancer that is advanced and/or metastatic disease
- •Participant who is planned to have gemcitabine therapy at the proposed doses because he/she was not able to benefit from standard therapy and/or therapies known to provide clinical benefit or there is no standard therapy for the advanced and/or metastatic disease globally
- •Have given written informed consent prior to any study-specific procedures
- •Have adequate hematologic, hepatic and renal function
- •Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale
- •Have discontinued all previous therapies for cancer, including chemotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 30 days (42 days for mitomycin C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy
- •Prior radiation therapy for treatment of cancer is allowed to less than 25% of the bone marrow, and participants must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 30 days prior to study enrollment
- •Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the study and for 3 months after the last infusion of study drug
- •Females with child bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have had a negative urine pregnancy test less than 7 days prior to the enrollment
- •Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion Criteria
- •Are currently enrolled in, or discontinued within the last 30 days from, a clinical study involving an off-label use of an investigational drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the participant or his/her ability to complete the study
- •Have interstitial pneumonitis or pulmonary fibrosis, or previous history of them
- •Have symptomatic central nervous system malignancy or metastasis
- •Have current active infection
- •Females who are pregnant or lactating
- •Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb)
- •Participants with acute or chronic leukemia or with any other disease likely to have a significant bone marrow infiltration
- •Have previously completed or withdrawn from this study or any other study investigating LY2603618 or any other checkpoint kinase (Chk1) inhibitor
- •Have known allergy to gemcitabine or LY2603618 or any ingredient of gemcitabine or LY2603618 (like Captisol®)
Arms & Interventions
LY2603618 + Gemcitabine
Experimental
Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.
Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met.
Intervention: LY2603618 (Drug)
LY2603618 + Gemcitabine
Experimental
Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.
Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met.
Intervention: Gemcitabine (Drug)
Outcomes
Primary Outcomes
Number of Participants With Dose Limiting Toxicity (DLT)
Time Frame: Cycle 1 (28 Days)
DLT is defined as adverse event (AE) during Cycle 1 (Days 1 through 28) that was possibly related to the study drug and toxicities considered by the investigator as dose limiting. A summary of other nonserious AEs, and all serious adverse events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
Secondary Outcomes
- Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2603618(Cycle 1 (days 2 and 16) & 2 (day 2): Predose, End of Infusion, 1 hour (h), 3h, 6h, 24h (days 3 and 17), 48h (days 4 and 18 cycle 1 only), 72h (days 5 and 19))
- PK: Cmax of Gemcitabine(Cycle 1 (days 1 and 15) & 2 (day 1): Predose, End of Infusion, 10 minutes (m), 30m, 60m, 120m)
- Number of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Best Overall Response)(Baseline to Measured Progressive Disease (Up to 52 Months))
- PK: Area Under the Plasma Concentration vs. Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2603618(Cycle 1 (days 2 and 16) & 2 (day 2): Predose, End of Infusion, 1 hour (h), 3h, 6h, 24h (days 3 and 17), 48h (days 4 and 18 cycle 1 only), 72h (days 5 and 19))
- PK: Cmax of Gemcitabine Metabolite Deoxydifluorouridine (dFdU)(Cycle 1 (days 1 and 15) & 2 (day 1): Predose, End of Infusion, 10 minutes (m), 30m, 60m, 120m)
- PK: AUC(0-∞) of Gemcitabine(Cycle 1 (days 1 and 15) & 2 (day 1): Predose, End of Infusion, 10 minutes (m), 30m, 60m, 120m)
- PK: AUC(0-∞) of Gemcitabine Metabolite dFdU(Cycle 1 (days 1 and 15) & 2 (day 1): Predose, End of Infusion, 10 minutes (m), 30m, 60m, 120m)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of Advanced or Metastatic Non-small Cell Lung CancerNon Small Cell Lung CancerNCT00988858Eli Lilly and Company55
Completed
Phase 1
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic CancerAdvanced CancerMetastatic CancerColorectal CancerNon-small Cell Lung CancerNCT02860780Eli Lilly and Company9
Completed
Phase 1
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With CancerCancerNCT00415636Eli Lilly and Company31
Terminated
Phase 1
A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsSolid TumorBreast CancerColon CancerCholangiocarcinomaSoft Tissue SarcomaNCT02784795Eli Lilly and Company94
Completed
Phase 1
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)Alzheimer's DiseaseNCT02754830Eli Lilly and Company72